ES2072490T3 - Procedimiento para la pasteurizacion de la proteina tisular pp4. - Google Patents

Procedimiento para la pasteurizacion de la proteina tisular pp4.

Info

Publication number
ES2072490T3
ES2072490T3 ES91112381T ES91112381T ES2072490T3 ES 2072490 T3 ES2072490 T3 ES 2072490T3 ES 91112381 T ES91112381 T ES 91112381T ES 91112381 T ES91112381 T ES 91112381T ES 2072490 T3 ES2072490 T3 ES 2072490T3
Authority
ES
Spain
Prior art keywords
pasteurization
procedure
tissue protein
esp
opt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91112381T
Other languages
English (en)
Inventor
Hartmut Dr Lobermann
Chritiane Bornmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2072490T3 publication Critical patent/ES2072490T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA PASTERIZACION DE PROTEINAS DE TEJIDO PP4 EN PRESENCIA DE ESTABILIZADORES.
ES91112381T 1986-12-18 1987-12-15 Procedimiento para la pasteurizacion de la proteina tisular pp4. Expired - Lifetime ES2072490T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863643182 DE3643182A1 (de) 1986-12-18 1986-12-18 Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4

Publications (1)

Publication Number Publication Date
ES2072490T3 true ES2072490T3 (es) 1995-07-16

Family

ID=6316431

Family Applications (2)

Application Number Title Priority Date Filing Date
ES87118598T Expired - Lifetime ES2042532T3 (es) 1986-12-18 1987-12-15 Procedimiento para preparar un agente destinado a la terapia o profilaxis de trastornos hemostaticos.
ES91112381T Expired - Lifetime ES2072490T3 (es) 1986-12-18 1987-12-15 Procedimiento para la pasteurizacion de la proteina tisular pp4.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES87118598T Expired - Lifetime ES2042532T3 (es) 1986-12-18 1987-12-15 Procedimiento para preparar un agente destinado a la terapia o profilaxis de trastornos hemostaticos.

Country Status (13)

Country Link
US (1) US5097019A (es)
EP (3) EP0457370B1 (es)
JP (1) JP2532535B2 (es)
KR (1) KR960007922B1 (es)
AT (2) ATE75618T1 (es)
AU (1) AU622102B2 (es)
CA (1) CA1338395C (es)
DE (3) DE3643182A1 (es)
DK (3) DK167900B1 (es)
ES (2) ES2042532T3 (es)
FI (1) FI91218C (es)
GR (1) GR3005247T3 (es)
PT (1) PT86393B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416151B (sv) * 1978-10-03 1980-12-01 Ake Gunnar Bolmgren Byggelement jemte mursten for tillverkning av elementet
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4003773A1 (de) * 1990-02-08 1991-08-14 Behringwerke Ag Verfahren zur reinigung von lipocortinen
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
DE19734648A1 (de) 1997-08-11 1999-02-18 Dade Behring Marburg Gmbh Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
EP1379266B1 (en) * 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461833A (en) * 1982-06-23 1984-07-24 University Patents, Inc. Chromatographically purifying proteolytic procoagulant enzyme from animal tissue extract
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
DE3724726A1 (de) * 1987-07-25 1989-02-02 Behringwerke Ag Verfahren zur reinigung des plazentaren gewebeproteins pp4
US4896172A (en) * 1987-11-20 1990-01-23 Canon Kabushiki Kaisha Liquid injection recording apparatus including recording liquid circulation control

Also Published As

Publication number Publication date
FI91218C (fi) 1994-06-10
DK665787A (da) 1988-06-19
EP0271885A3 (en) 1988-09-21
DK665787D0 (da) 1987-12-17
ATE75618T1 (de) 1992-05-15
DE3643182A1 (de) 1988-06-30
FI875518A (fi) 1988-06-19
DK36093D0 (da) 1993-03-26
DE3751281D1 (de) 1995-06-08
ATE121940T1 (de) 1995-05-15
FI91218B (fi) 1994-02-28
AU8264687A (en) 1988-06-23
JP2532535B2 (ja) 1996-09-11
KR960007922B1 (ko) 1996-06-17
DE3778852D1 (de) 1992-06-11
PT86393B (pt) 1990-11-20
GR3005247T3 (es) 1993-05-24
EP0457371A1 (de) 1991-11-21
FI875518A0 (fi) 1987-12-16
DK36093A (da) 1993-03-26
DK35993D0 (da) 1993-03-26
JPS63165328A (ja) 1988-07-08
PT86393A (en) 1988-01-01
DK35993A (da) 1993-03-26
KR880007088A (ko) 1988-08-26
EP0271885B1 (de) 1992-05-06
EP0271885A2 (de) 1988-06-22
EP0457370B1 (de) 1995-05-03
US5097019A (en) 1992-03-17
DK167900B1 (da) 1994-01-03
ES2042532T3 (es) 1993-12-16
AU622102B2 (en) 1992-04-02
EP0457370A1 (de) 1991-11-21
CA1338395C (en) 1996-06-11

Similar Documents

Publication Publication Date Title
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
ATE86475T1 (de) Verwendung von milch-glycoproteinen zur mundhygiene.
PT1133238E (pt) Processo de preapacao de uma composicao proteica e de uma formula infantil que a contem
ATE114971T1 (de) Zwei-stufen-verfahren zur heilung schmerzenfreier wunden, sowie wässriges medium und topische salbe zur verwendung dazu.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
ATE112937T1 (de) Sterilfiltrierte kolostralmilch.
DE3379159D1 (en) Process for pasteurizing an antihaemophilic cryoprecipitate, and antihaemophilic cryoprecipitate so obtained
DE68904462T2 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
DE3786838D1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern.
ATE336992T1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
ES2080155T3 (es) Procedimiento de pasteurizacion y cola pasteurizada para unir tejidos humano o animal.
DE69117920T2 (de) Zusammensetzung zur stabilisierung von blutplasma im laufe der pasteurisation
SU1138167A1 (ru) Способ лечени асептических послеоперационных ран
DK169190A (da) Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
RU92003760A (ru) Устройство для индивидуального лечения
ES2008625A6 (es) Procedimiento para la obtencion de concentrados de aminoacidos; solubles y de alto grado de pureza, a partir de subproductos proteicos animales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 457370

Country of ref document: ES